Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Gemzar approved in U.S.

May 24, 1996

Glaxo Wellcome's new dihydrofolate reductase inhibitor 195U89

May 24, 1996

MGI-114 receives patent protection in U.S.

May 24, 1996

Ribonucleotide reductase inhibitor 3-AP in development at Vion

May 17, 1996

BioChem Therapeutic will codevelop VX-710 in Canada

May 17, 1996

SmithKline Beecham claims hemoregulatory agents

May 17, 1996

Mitsui Toatsu claims antitumor trifluorothymidine derivatives

May 17, 1996

Patent coverage obtained for Immune Response's cell therapy for B cell lymphoma

May 17, 1996

Supplemental NDA filed for Novantrone in U.S.

May 17, 1996

Platinum complexes claimed by Nippon Kayaku

May 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...